Berry Genomics Co Ltd
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcri… Read more
Berry Genomics Co Ltd - Asset Resilience Ratio
Berry Genomics Co Ltd (000710) has an Asset Resilience Ratio of 0.45% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2024)
This chart shows how Berry Genomics Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Berry Genomics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥10.48 Million | 0.45% |
| Total Liquid Assets | CN¥10.48 Million | 0.45% |
Asset Resilience Insights
- Limited Liquidity: Berry Genomics Co Ltd maintains only 0.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Berry Genomics Co Ltd Industry Peers by Asset Resilience Ratio
Compare Berry Genomics Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
|
Bionet
TWO:1784 |
Diagnostics & Research | 38.62% |
Annual Asset Resilience Ratio for Berry Genomics Co Ltd (1997–2024)
The table below shows the annual Asset Resilience Ratio data for Berry Genomics Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.71% | CN¥17.03 Million | CN¥2.38 Billion | +0.21pp |
| 2023-12-31 | 0.51% | CN¥13.86 Million | CN¥2.74 Billion | +0.36pp |
| 2022-12-31 | 0.14% | CN¥4.51 Million | CN¥3.20 Billion | +0.03pp |
| 2021-12-31 | 0.11% | CN¥3.81 Million | CN¥3.52 Billion | -0.01pp |
| 2020-12-31 | 0.12% | CN¥3.81 Million | CN¥3.24 Billion | -0.09pp |
| 2019-12-31 | 0.21% | CN¥6.43 Million | CN¥3.07 Billion | -20.04pp |
| 2016-12-31 | 20.25% | CN¥111.00 Million | CN¥548.04 Million | -29.86pp |
| 2015-12-31 | 50.11% | CN¥250.00 Million | CN¥498.88 Million | +48.16pp |
| 1998-12-31 | 1.95% | CN¥6.00 Million | CN¥307.78 Million | +0.22pp |
| 1997-12-31 | 1.72% | CN¥5.00 Million | CN¥289.91 Million | -- |